Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 10/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660126 | 0.82 | KHK (0.48) | KHKTRPV4CYP11B1CYP11B2ADRB2 | |
| SCHEMBL1128865 | 0.82 | TRPV4 (0.46) | KHKTRPV4ESR1ESR2CNR2 | |
| SCHEMBL6661759 | 0.80 | KHK (0.47) | KHKTRPV4CYP11B1CYP11B2ADRB2 | |
| SCHEMBL332547 | 0.80 | TRPV4 (0.56) | KHKTRPV4CYP11B1CYP11B2ADRB2 | |
| SCHEMBL934418 | 0.76 | TRPV4 (0.50) | KHKTRPV4CYP11B1CYP11B2ADRB2 | |
| SCHEMBL29467996 | 0.76 | TRPV4 (0.50) | KHKTRPV4CYP11B1CYP11B2ADRB2 | |
| SCHEMBL3324301 | 0.75 | TRPV4 (0.41) | KHKTRPV4ESR1ESR2CNR2 | |
| SCHEMBL31267335 | 0.75 | KHK (0.43) | KHKTRPV4CYP11B1CYP11B2ADRB2 | |
| SCHEMBL2476965 | 0.75 | KHK (0.52) | KHKTRPV4CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL5846599 | 0.75 | KHK (0.43) | KHKTRPV4CYP11B1CYP11B2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| EP-1315733-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002020531-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| EP-0364797-B1 | N-aryl-nitrogenated heterocycles, process for their preparation and their use as herbicides | BAYER AG (DE) | 1994-02-16 | — | — | EP | disclosed |
| US-5221318-A | Crop plant selectivity | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
| US-5069711-A | PREEMERGENCE | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| EP-0364797-A2 | N-aryl-nitrogenated heterocycles, process for their preparation and their use as herbicides | BAYER AG (DE) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | KHK 874/4885TRPV4 3939/4885ESR1 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.